Multiple myeloma (MM) is an incurable blood cancer, leading to weakened immunity, bone damage, and other serious health ...

GSK's drive to resurrect its multiple myeloma therapy Blenrep has continued with new data from the DREAMM-7 trial showing an ...

Multiple Myeloma is a type of blood cancer that develops in plasma ... infections but also leads to the deterioration of ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

At the end of the treatment evaluation, they also looked at progression ... and dexamethasone for transplantation-eligible ...

J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...

The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...

The Department of Veterans Affairs has started the process to designate multiple myeloma and acute and chronic leukemias ...

Hamlet Gasoyan, MD, discussed the implications of a multiple myeloma study’s findings and their potential impact on clinical ...

If approved by the FDA, Darzalex Faspro may be the first treatment for smoldering multiple myeloma as compared to treating the disease once it progresses.

Multiple myeloma is the second most common hematologic malignancy, but there is a treatment gap for patients with disease ...

Newer treatments, including anti-CD38 monoclonal antibodies and immunomodulating agents, are becoming standard in multiple myeloma management. In patients with relapsed or refractory multiple myeloma, ...